Neurofibromatose

Die Symptome einer Neurofibromatose können in allen Altersklassen erstmals auftreten, häufig bereits in den ersten 3 Lebensdekaden, teilweise mit sehr langsamer Entwicklung über Jahrzehnte oder rasch progredient innerhalb weniger Monate. Unter anderem diese unterschiedliche Entwicklungsdynamik kann die Diagnose einer Neurofibromatose ebenso wie die Entwicklung eines individuellen Therapiekonzeptes erschweren.

Abstract

Background & Focus While the Neurofibromatoses have been observed and classified by their phenotypes for several centuries, their great variability constitutes a considerable challenge in diagnostics and therapy selection. This article focuses on highlighting the three most frequent sub-types NF1, NF2 and NF3.

Methods All three NF types are outlined by the following measures: the history of their clinical detection, the typical appearance, the underlying genetic constitution and its consequences, the official diagnostic criteria, the mandatory diagnostic steps and finally the treatment opportunities and specific risks.

Results About 50% of NF patients have a positive family history and the other 50% are the first symptomatic generations and suffer from new mutations. A considerable (unknown) number of patients do not exhibit a complete genetic NF constitution, but have a so-called mosaic sub-form with only a limited number of cells being genetically affected and prone to tumorous changes. The neurofibromatoses are neuro-cutaneous diseases with manifestations at the skin and nervous system, except for NF 3, where the skin and eyes are never affected. Skin and eye manifestations, especially pigmentation disturbances, mostly started early in childhood and adolescence. The underlying genetic constitutions, on chromosome 17 in NF1 and on chromosome 22 in NF2 and NF3, cause a defect in tumor suppressor genes and lead to excessive proliferation of Schwann cells. Major features are tumors of the peripheral nerves, including cranial and spinal nerves leading to tumors with considerable nerve, brain and spinal cord compression and resulting in pain, sensory and motor deficits. A further variable disease feature may be neuropathy with neuropathic pain, related to tumor formation or even independent of it.

Although benign by histopathology and growing rather slowly, those tumors often cause progressive neurological deficit and loss of function. Loss of function may be prevented by adequate timing of therapy such as nerve decompression by microsurgical tumor resection or reduction, medication with immunotherapy or radiotherapy in selected cases. To date it is unknown why some tumors remained silent and stable while others progress and show periods of accelerated growth.

As a consequence, NF patients need to be accompanied by a specialized interdisciplinary NF team at long-term, with a clear-cut standardized protocol for clinical and imaging controls along with counseling and support in decision-making.

Further, NF patients may suffer from reactive depression due to the danger of losing essential neural functions, such as vision or audition or movement. And especially NF1 patients show characteristics of ADHS and other cognitive compromise in at least 50% of cases.

Conclusions As the neurofibromatosis belong to the so-called rare diseases, all patients with a suspicion or diagnosis of NF should get the opportunity to present to an interdisciplinary NF Center, mostly situated at University Hospitals, where competent counseling on the individual disease phenotype may be provided. Here the patients will be informed on the necessary diagnostic steps, their frequency as well as on practical steps in case of acute deterioration. Most NF centers are run by neurosurgeons or neurologists or pediatricians, working in a network with geneticists, neuro-radiologists, ophthalmologists, dermatologists, plastic and general surgeons, psychologists, psychiatrists and social work experts. They participate regularly in neuro-oncological tumor and sarcoma tumor boards, skull base tumor centers, comprehensive hearing centers, and deliver all the treatment opportunities provided by certified brain tumor centers, among those the inclusion in special diagnostic and treatment studies or the contact information to patient support groups.

Publication History

Article published online:
16 May 2023

• Literatur

• 1 Matthies C, Heinen C. Nerventumoren. In: Antoniadis G, Harhaus L, Assmus H (eds.) Chirurgie peripherer Nerven kompakt. Berlin: Springer; 2021: 329-358
• 2 Legius E, Messiaen L, Wolkenstein P. et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med 2021; 23: 1506-1513
• 3 Drouet A, Wolkenstein P, Lefaucheur JP. et al. Neurofibromatosis 1-associated neuropathies: a reappraisal. Brain 2004; 127: 1993-2009
• 4 Nielsen GCP. Malignant peripheral nerve sheath tumour, 5th edn. Lyon (France): International Agency for Research on Cancer IARC; 2020
• 5 Martin E, Coert JH, Flucke UE. et al. A nationwide cohort study on treatment and survival in patients with malignant peripheral nerve sheath tumours. Eur J Cancer 2020; 124: 77-87
• 6 Harati K, Goertz O, Pieper A. et al. Soft tissue sarcomas oft he extremities: surgical margins can be close as long as the resected tumor has no ink on it. Oncologist 2017; 22: 1400-1410
• 7 Matthies C, Brill S, Varallyay C. et al. Auditory brainstem implants in neurofibromatosis Type 2: Is open speech perception feasible?. J Neurosurg 2014; 120: 546-558
• 8 Plotkin SR, Merker VL, Halpin C. et al. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 2012; 33: 1046-1052
• 9 Kertels O, Breun M, Hänscheid H. et al. Peptide Receptor Radionuclide Therapy in Patients With Neurofibromatosis Type 2: Initial Experience. Clin Nucl Med 2021; 46: e312-e316
• 10 Nunes FP, Merker VL, Jennings D. et al. Bevacizumab treatment for meningeomas in NF2: a retrospective analysis of 15 patients. PLoS One 2013; 8: e59941
• 11 Evans DG, Birch JM, Ramsden RT. et al. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet 2006; 43: 289-294
• 12 Kehrer-Sawatzki H, Farschtschi S, Mautner VF. et al. The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis. Hum Genet 2017; 136: 129-148
• 13 MacCollin M, Chiocca EA, Evans DG. et al. Diagnostic criteria for schwannomatosis. Neurology 2005; 64: 1838-1845
• 14 Schraepen C, Donkersloot P, Duyvendak W. et al. What to know about schwannomatosis: a literature review. Br J Neurosurg 2020;
• 15 Hilton DA, Hanemann CO. Schwannomas and their pathogenesis. Brain Pathol 2014; 24: 205-220
• 16 Hulsebos TJM, Plomp AS, Wolterman RA. et al. Germline mutation of INI1/SMARCB1 in familial schwannomatosis. Acta Neuropathol 2007; 80: 805-810
• 17 Versteege I, Sévenet N, Lange J. et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998; 394: 203-206
• 18 Smith MJ, Isidor B, Beetz C. et al. Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis. Neurology 2015;
• 19 Guha D, Davidson B, Nadi M. et al. Management Of Peripheral Nerve Sheath Tumors: 17 Years Of Experience At Toronto Western Hospital. J Neurosurg 2018; 128: 1226-1234
• 20 Leitlinienprogramm Onkologie. S2k Leitlinie Diagnostik und Therapie peripherer Nerventumoren. AWMF-Registernummer 2022; 008-024
• 21 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Adulte Weichgewebesarkome, Leitlinienreport Version 1.01. AWMF Registernummer: 032/044OL. 2021